These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 35910377)

  • 21. Effects of serine protease inhibitors on viability and morphology of Leishmania (Leishmania) amazonensis promastigotes.
    Silva-Lopez RE; Morgado-Díaz JA; Chávez MA; Giovanni-De-Simone S
    Parasitol Res; 2007 Nov; 101(6):1627-35. PubMed ID: 17726617
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activity-based protein profiling of human and
    Davison D; Howell S; Snijders AP; Deu E
    iScience; 2022 Sep; 25(9):104996. PubMed ID: 36105595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exploring direct and indirect targets of current antileishmanial drugs using a novel thermal proteomics profiling approach.
    Ibarra-Meneses AV; Corbeil A; Wagner V; Beaudry F; do Monte-Neto RL; Fernandez-Prada C
    Front Cell Infect Microbiol; 2022; 12():954144. PubMed ID: 35992178
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A chloroquinoline derivate presents effective in vitro and in vivo antileishmanial activity against Leishmania species that cause tegumentary and visceral leishmaniasis.
    Sousa JKT; Antinarelli LMR; Mendonça DVC; Lage DP; Tavares GSV; Dias DS; Ribeiro PAF; Ludolf F; Coelho VTS; Oliveira-da-Silva JA; Perin L; Oliveira BA; Alvarenga DF; Chávez-Fumagalli MA; Brandão GC; Nobre V; Pereira GR; Coimbra ES; Coelho EAF
    Parasitol Int; 2019 Dec; 73():101966. PubMed ID: 31362122
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cysteine protease inhibitors as chemotherapy for parasitic infections.
    McKerrow JH; Engel JC; Caffrey CR
    Bioorg Med Chem; 1999 Apr; 7(4):639-44. PubMed ID: 10353643
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of NanoLuc-PEST expressing Leishmania mexicana as a new drug discovery tool for axenic- and intramacrophage-based assays.
    Berry SL; Hameed H; Thomason A; Maciej-Hulme ML; Saif Abou-Akkada S; Horrocks P; Price HP
    PLoS Negl Trop Dis; 2018 Jul; 12(7):e0006639. PubMed ID: 30001317
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activity-based protein profiling reveals active serine proteases that drive malignancy of human ovarian clear cell carcinoma.
    Mehner C; Hockla A; Coban M; Madden B; Estrada R; Radisky DC; Radisky ES
    J Biol Chem; 2022 Aug; 298(8):102146. PubMed ID: 35716777
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Two phylogenetically divergent isocitrate dehydrogenases are encoded in Leishmania parasites. Molecular and functional characterization of Leishmania mexicana isoenzymes with specificity towards NAD
    Giordana L; Nowicki C
    Mol Biochem Parasitol; 2020 Nov; 240():111320. PubMed ID: 32980452
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In silico Leishmania proteome mining applied to identify drug target potential to be used to treat against visceral and tegumentary leishmaniasis.
    Chávez-Fumagalli MA; Lage DP; Tavares GSV; Mendonça DVC; Dias DS; Ribeiro PAF; Ludolf F; Costa LE; Coelho VTS; Coelho EAF
    J Mol Graph Model; 2019 Mar; 87():89-97. PubMed ID: 30522092
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Repurposing Lansoprazole and Posaconazole to treat leishmaniasis: Integration of in vitro testing, pharmacological corroboration, and mechanisms of action.
    Gupta Y; Goicoechea S; Romero JG; Mathur R; Caulfield TR; Becker DP; Durvasula R; Kempaiah P
    J Food Drug Anal; 2022 Mar; 30(1):128-149. PubMed ID: 35647721
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New aziridine-based inhibitors of cathepsin L-like cysteine proteases with selectivity for the Leishmania cysteine protease LmCPB2.8.
    Fey P; Chartomatsidou R; Kiefer W; Mottram JC; Kersten C; Schirmeister T
    Eur J Med Chem; 2018 Aug; 156():587-597. PubMed ID: 30029081
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CRISPR/Cas9 in Leishmania mexicana: A case study of LmxBTN1.
    Ishemgulova A; Hlaváčová J; Majerová K; Butenko A; Lukeš J; Votýpka J; Volf P; Yurchenko V
    PLoS One; 2018; 13(2):e0192723. PubMed ID: 29438445
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In-cell selectivity profiling of serine protease inhibitors by activity-based proteomics.
    Gillet LC; Namoto K; Ruchti A; Hoving S; Boesch D; Inverardi B; Mueller D; Coulot M; Schindler P; Schweigler P; Bernardi A; Gil-Parrado S
    Mol Cell Proteomics; 2008 Jul; 7(7):1241-53. PubMed ID: 18364346
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An inhibitor-driven study for enhancing the selectivity of indirubin derivatives towards leishmanial Glycogen Synthase Kinase-3 over leishmanial cdc2-related protein kinase 3.
    Efstathiou A; Gaboriaud-Kolar N; Smirlis D; Myrianthopoulos V; Vougogiannopoulou K; Alexandratos A; Kritsanida M; Mikros E; Soteriadou K; Skaltsounis AL
    Parasit Vectors; 2014 May; 7():234. PubMed ID: 24886176
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antileishmanial Drug Development: A Review of Modern Molecular Chemical Tools and Research Strategies.
    Mantravadi PK; Parthasarathy A; Kalesh K
    Curr Med Chem; 2021; 28(31):6337-6357. PubMed ID: 33238841
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A parasite rescue and transformation assay for antileishmanial screening against intracellular Leishmania donovani amastigotes in THP1 human acute monocytic leukemia cell line.
    Jain SK; Sahu R; Walker LA; Tekwani BL
    J Vis Exp; 2012 Dec; (70):. PubMed ID: 23299097
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DNA Topoisomerases of Leishmania Parasites; Druggable Targets for Drug Discovery.
    Reguera RM; Elmahallawy EK; García-Estrada C; Carbajo-Andrés R; Balaña-Fouce R
    Curr Med Chem; 2019; 26(32):5900-5923. PubMed ID: 29773051
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proteomic approaches for drug discovery against tegumentary leishmaniasis.
    Negrão F; Eberlin MN; Giorgio S
    Biomed Pharmacother; 2017 Nov; 95():577-582. PubMed ID: 28869896
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Functional attribution of LdISP, an endogenous serine protease inhibitor from Leishmania donovani in promoting infection.
    Alam MN; Chakraborti S; Paik D; Bagchi A; Chakraborti T
    Biochimie; 2018 Apr; 147():105-113. PubMed ID: 29366936
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antileishmanial effect of new indeno-1,5-naphthyridines, selective inhibitors of Leishmania infantum type IB DNA topoisomerase.
    Tejería A; Pérez-Pertejo Y; Reguera RM; Balaña-Fouce R; Alonso C; Fuertes M; González M; Rubiales G; Palacios F
    Eur J Med Chem; 2016 Nov; 124():740-749. PubMed ID: 27639365
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.